Publication: The immunohistochemical expression of c-met is an independent predictor of survival in patients with glioblastoma multiforme
dc.contributor.buuauthor | Ölmez, O. F. | |
dc.contributor.buuauthor | Çubukçu, E. | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.buuauthor | Evrensel, T. | |
dc.contributor.buuauthor | EVRENSEL, TÜRKKAN | |
dc.contributor.buuauthor | Kurt, M. | |
dc.contributor.buuauthor | Avcı, N. | |
dc.contributor.buuauthor | Tolunay, S. | |
dc.contributor.buuauthor | TOLUNAY, ŞAHSİNE | |
dc.contributor.buuauthor | Bekar, Ahmet | |
dc.contributor.buuauthor | BEKAR, AHMET | |
dc.contributor.buuauthor | Deligönül, Adem | |
dc.contributor.buuauthor | DELİGÖNÜL, ADEM | |
dc.contributor.buuauthor | Hartavi, M. | |
dc.contributor.buuauthor | Alkış, N. | |
dc.contributor.buuauthor | Manavoğlu, O. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/ Onkoloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/NöroPatoloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. | |
dc.contributor.researcherid | ABX-9081-2022 | |
dc.contributor.researcherid | AAJ-1027-2021 | |
dc.contributor.researcherid | AAA-3961-2020 | |
dc.contributor.researcherid | AAI-1612-2021 | |
dc.date.accessioned | 2024-08-15T08:01:23Z | |
dc.date.available | 2024-08-15T08:01:23Z | |
dc.date.issued | 2014-02-01 | |
dc.description.abstract | Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols.Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 +/- A 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures.Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 +/- A 2.3 vs. 22.6 +/- A 2.5 months, respectively, p < 0.01) and PFS (12.3 +/- A 2.1 vs. 19.1 +/- A 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05).Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care. | |
dc.identifier.doi | 10.1007/s12094-013-1059-4 | |
dc.identifier.endpage | 177 | |
dc.identifier.issn | 1699-048X | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 173 | |
dc.identifier.uri | https://doi.org/10.1007/s12094-013-1059-4 | |
dc.identifier.uri | https://hdl.handle.net/11452/44043 | |
dc.identifier.volume | 16 | |
dc.identifier.wos | 000330964300009 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Springer International Publishing Ag | |
dc.relation.journal | Clinical & Translational Oncology | |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi | |
dc.subject | Hepatocyte growth-factor | |
dc.subject | Kinase inhibitor | |
dc.subject | Prognostic-significance | |
dc.subject | Cancer | |
dc.subject | Gliomas | |
dc.subject | Target | |
dc.subject | Therapy | |
dc.subject | Glioblastoma multiforme | |
dc.subject | Prognosis | |
dc.subject | C-met | |
dc.subject | Immunohistochemistry | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.title | The immunohistochemical expression of c-met is an independent predictor of survival in patients with glioblastoma multiforme | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication | eceff514-6af7-4c3b-a146-b77546565a6c | |
relation.isAuthorOfPublication | 13dc6562-e9fe-42fa-8973-dcd80444844e | |
relation.isAuthorOfPublication | e929e321-8731-462f-8655-65e237321fef | |
relation.isAuthorOfPublication | edfc19d5-ce9e-4fbd-8a24-07492003c264 | |
relation.isAuthorOfPublication.latestForDiscovery | f971677f-09c5-4463-bf01-3c6341fbe5f7 |